AKTX Stock — Akari Therapeutics PLC

Akari Therapeutics PLC (AKTX)

Updated October 16, 2026.

AKTX is a Stock. Total return is 32620.0% over the past 13.4 years, 32130.1 points ahead of SPY at 489.9%.

Akari Therapeutics is an oncology company developing antibody-drug conjugates for cancer treatment, with a lead payload called PH1 designed to disrupt RNA splicing in cancer cells and trigger immune responses. Its primary product candidate, AKTX-101, combines this payload with a trop2-targeting antibody to treat various solid tumors including lung, breast, bladder, and pancreatic cancers, while a secondary candidate, AKTX-102, is a bispecific ADC also utilizing the PH1 payload. The company does not currently have an established distribution schedule.

AKTX performance versus SPY

Price and return data through 2026-10-16.

Total return is 32620.0% over the past 13.4 years, 32130.1 points ahead of SPY at 489.9%. Over the past year its total return — price change plus distributions reinvested — is -73.4%. Its deepest 1-year drawdown was 90.7%.

AKTX key facts

Asset type

Stock

Asset class

Equity

Inception date

05/07/2013

Distribution frequency

None

Last close

$8.18 (as of 2026-10-16)

Market cap

$18,692,650

Average volume

21700.0

Beta

1.44

Payout ratio

0.0%

EPS

$0.00

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AKTX risks and drawbacks

The deepest 1-year drawdown on record here is 90.7%.

Who may consider AKTX — and who may not

It is a weaker fit for investors who need monthly cash flow (AKTX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on AKTX

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions